Compare Viatris Inc (VTRS) vs Financial Select Sector SPDR Fund (XLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Viatris Inc vs Financial Select Sector SPDR Fund — how do they compare? Viatris Inc trades at $16.06 (market cap $18.49B), while Financial Select Sector SPDR Fund trades at $58.29. The key difference: Viatris Inc pays a 2.98% dividend while Financial Select Sector SPDR Fund pays none, and Financial Select Sector SPDR Fund is trading nearer its 52-week high, Viatris Inc nearer its low. Which is the better fit depends on your goals.
| VTRS | XLF | |
|---|---|---|
Market Cap | $18.49B | — |
Sector | Health | — |
52-Week High | $17.86 | $58.01 |
52-Week Low | $9.49 | $47.80 |
Enterprise Value | $30.61B | — |
Dividend Yield | 2.98% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Viatris (VTRS) trades at $16.04, down 1.47% on the day, with a mixed technical outlook showing bullish overall signals but bearish moving averages. The company has delivered three consecutive quarterly earnings beats, with Q2 2026 EPS of $0.69 exceeding expectations by 14.8%. Recent FDA approval for Gwyn Lo contraceptive patch and divestiture of Tyrvaya nasal spray demonstrate strategic portfolio optimization. Revenue trends show stabilization after declining from $16.3B in 2022 to $14.3B in 2025, with 2026 projections at $14.7B.
While Viatris shows operational strength with consistent cash flow generation and debt reduction, the company faces profitability challenges with negative net income margins and elevated P/E ratio of 236.2. Analyst sentiment is cautiously optimistic with 30.8% buy ratings, though the majority (61.5%) recommend hold. Key risks include ongoing margin pressure, generic drug pricing headwinds, and execution of strategic initiatives amid competitive pharmaceutical landscape.
XLF trades at $57.91, up 0.17% with a bullish technical outlook as it crosses above its 200-day moving average of $52.72. The ETF recently hit record highs amid sector rotation into financials, with strong inflows and positive sentiment around AI financing opportunities. Moving averages signal strong bullish momentum while oscillators remain neutral.
The financial sector ETF benefits from Wall Street's expanding role in AI infrastructure funding and strong bank earnings. Key risks include valuation concerns and market volatility. Technical support sits at $57 with resistance at $58. The outlook remains positive given sector momentum and institutional interest.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →About Financial Select Sector SPDR Fund
The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: diversified financial services; insurance; banks; capital markets; mortgage real estate investment trusts; consumer finance; thrifts; and mortgage finance. The fund is non-diversified.
Read more on XLF →
